Who is sponsoring NCT00748371?

NCT00748371 is sponsored by Vanderbilt University.

What condition does NCT00748371 study?

NCT00748371 studies Platelet Aggregation.

What drugs are being tested in NCT00748371?

Interventions: aspirin, aspirin, placebo.

What is the status of NCT00748371?

NCT00748371 is currently TERMINATED.

Last reviewed 2017-04-10 · How we verify

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371 Phase 4 TERMINATED

Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help people who are at risk for heart attack or stroke.

Details

Lead sponsor	Vanderbilt University
Phase	Phase 4
Status	TERMINATED
Enrolment	51
Start date	2004-06
Completion	2011-02

Conditions

Platelet Aggregation

Interventions

aspirin
aspirin
placebo

Primary outcomes

Comparison of platelet aggregation, serum thromboxane B2 (TxB2) levels, urinary thromboxane metabolite (Tx-M) levels, and urinary prostacyclin metabolite (PGI-M) levels over time and across dose ranges. — 11 weeks

Countries

United States